Boston, MA 05/19/2014 (wallstreetpr) – The leading biopharmaceutical giant AbbVie (NYSE:ABBV) announces that Michael Severino will be its new Executive Vice President of research and development department. Along with this responsibility, he will also make sure that the scientific issues of the company go on in the right direction. He will work as a Chief Scientist Officer for the company. ABBV is one of the leading companies and top emerging companies in this field; thus the responsibilities fulfilled here will surely play a vital role in the career of Severino.
His responsibilities at the company will include regulatory affairs, medical proceedings, and R&D experiment. Please note that AbbVie (NYSE:ABBV) has more than 7000 employees globally who are working in the research and development department researching on some of the most needed medicines for the betterment of the patients. Severino has a vast experience in biotechnology and genomics; thus the company can take advantage of his experience and touch newer heights.
Severino served as the Chief Medical Officer in his last company, taking care of clinical development strategy across several areas like immunology, oncology, neuroscience, and cardiovascular disease. He has expertise in various research related activities too that he can use for the betterment of the AbbVie (NYSE:ABBV).
Medical and biotech industry is growing with great speed globally and is expected to touch the never before heights in the next five years. In such situation when there are hundreds of opportunities available for the company, the experience and knowledge of Michael Severino will surely make a difference. One more point which should be paid attention to is that the company has done quite good in recent years, especially in the last one year; thus there are chances of increased revenue and profit figures in the coming quarters.
All the investors will have to give Michael some time to turn his expertise into results. So the results of Q2 will give a clear picture about his performance in AbbVie (NYSE:ABBV).
